Imfinzi data tee up battle with Tecentriq in small-cell lung cancer

9 September 2019

Detailed results from the Phase III CASPIAN trial show that the checkpoint inhibitor Imfinzi (durvalumab) performed well as a first-line option for people with extensive-stage small cell lung cancer (SCLC).

Adding Imfinzi to standard of care chemotherapy resulted in a reduction in risk of death by 27%, with median overall survival (OS) of 13 months, compared with just over 10 months for the control group.

Developer AstraZeneca (LSE: AZN) presented the data just days after cancer giant Roche (ROG: SIX) won European approval for its rival option Tecentriq (atezolizumab), in the same indication.

This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.

Try before you buy

Free

7 day trial access

Take a Free Trial

All the news that moves the needle in pharma and biotech
Exclusive features, podcasts, interviews, data analyses and commentary from our global network of life sciences reporters.
Receive The Pharma Letter daily news bulletin, free forever.

Become a subscriber

£820

Or £77 per month

Subscribe Now

Unfettered access to industry-leading news, commentary and analysis in pharma and biotech.
Updates from clinical trials, conferences, M&A, licensing, financing, regulation, patents & legal, executive appointments, commercial strategy and financial results.
Daily roundup of key events in pharma and biotech.
Monthly in-depth briefings on Boardroom appointments and M&A news.
Choose from a cost-effective annual package or a flexible monthly subscription

The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed

Chairman, Sanofi Aventis UK